In the world of exponential data and digital disruption, there are more stakeholders involved in R&D than ever before. Traditional business models across the drug discovery and development value chain are transitioning at an increasingly rapid pace. Likewise, the diversification of product pipelines has expanded beyond drugs to increasingly include medical devices, big data, and digital tools, through which we can better engage patients and harness the best of medicine. In this session, we take a look at this new field: who is involved, how are they working together, and what does this mean for the future of clinical trials from Academic, Pharmaceutical, Technology, and Regulatory perspectives? Likewise, what are the updates around the new Medical Device Regulations (MDR) – and how should SMEs prepare to take their first big steps towards getting their device(s) on the market?